Intuitive Surgical background on robotics, shares watched by Nasdaq investors
27.06.2026 - 14:25:19 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 14:24.
Intuitive Surgical, Inc. (US46120E6023) is one of the most closely followed names in robotic-assisted surgery on the Nasdaq. The company draws sustained analyst attention as investors monitor growth in installed systems, procedures and recurring revenue streams.
How Intuitive Surgical earns its money
Intuitive Surgical generates revenue primarily from sales and placements of its da Vinci surgical systems, as well as recurring income from instruments, accessories and services tied to each procedure. According to the company, more than 8,000 da Vinci systems are installed worldwide across hospitals and surgical centers. Company filings describe the revenue split between systems, instruments and services.
The recurring element is central: each da Vinci procedure consumes single-use or limited-use instruments and accessories, providing Intuitive Surgical with a stream of revenue that scales with procedure volume rather than just system placements. This model differentiates the company from some capital-equipment peers and supports relatively high gross margins on the instruments and accessories segment.
Analyst focus on procedures and margins
Equity analysts typically track three core operating metrics at Intuitive Surgical: procedure growth, system placements and average selling prices. On recent conference calls, management has emphasized growth in general surgery procedures, such as hernia repairs and colorectal operations, in addition to urology and gynecology, which were early drivers of robotic adoption. A Reuters overview of the sector notes that procedure growth is a key valuation driver for robotic surgery stocks.
Margin development also remains in focus. The mix between capital sales and recurring revenue, as well as investments in R&D and training, affect operating leverage over time. Analysts from large houses such as Goldman Sachs and Morgan Stanley regularly adjust their earnings models for Intuitive Surgical when the company reports quarterly results or updates its procedure-growth assumptions.
All news and analysis on the Intuitive Surgical, Inc. shares
Further articles, regulatory filings and background information on the Intuitive Surgical, Inc. stock can be found in the dedicated topic overview for this ISIN.
The product behind the stock
The flagship product at Intuitive Surgical is the da Vinci surgical system, a robotic platform that enables minimally invasive surgery through small incisions. Surgeons control articulated instruments at a console, while the system provides a high-definition, three-dimensional view of the operating field.
The listing in brief
Intuitive Surgical, Inc. stock trades on the Nasdaq under the ticker ISRG in US dollars; recent market data place the shares among the larger constituents of the US medical devices sector by market capitalization.
Intuitive Surgical, Inc. at a glance
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- WKN: 888024
- Ticker: ISRG
- Trading venue: Nasdaq
- Price (as of 2026-06-27, 12:00): 420.00 USD
- Market cap: 150000000000 USD (as of 2026-06-27)
- Sector / industry: Health Care Equipment
- Index membership: NASDAQ-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
